ColoSense
Colorectal Cancer Screening
Key Facts
About Geneoscopy
Geneoscopy is a commercial-stage diagnostics company developing noninvasive tests for gastrointestinal diseases, anchored by its proprietary stool-derived eukaryotic RNA (seRNA) platform. The company achieved a major milestone in 2024 with FDA approval for its lead product, ColoSense, a colorectal cancer screening test, and subsequently secured a $105 million Series C financing round in early 2025. Founded in 2015 by sibling duo Andrew Barnell (MBA) and Dr. Erica Barnell (MD/PhD), Geneoscopy aims to address significant gaps in screening adherence and health equity by providing convenient, effective alternatives to invasive procedures like colonoscopies. The company is also exploring applications of its platform in inflammatory bowel disease and other GI conditions through research partnerships.
View full company profileTherapeutic Areas
Other Colorectal Cancer Screening Drugs
| Drug | Company | Phase |
|---|---|---|
| Shield (ECLIPSE Study) | Guardant Health | FDA Approved |
| Urine cfDNA Test for Colon Cancer Screening | JBS Science | Development |
| iFOB | Pangea Laboratory | Commercial |
| ColoHealth | New Day Diagnostics | Approved |
| CRC Screening Program | Polymedco | Commercial |
| SimpleScreen CRC | Freenome | Commercial (as LDT) |
| ColoScape™ / QuantiDNA™ | DiaCarta | Commercial |
| At-Home Colorectal Cancer Screening | SNT Biotech | Commercial |
| FIT System & Assay Development | Sentinel Diagnostics | Commercial |
| Next-Generation Cologuard® | Exact Sciences | Development |
| ColoAlert® | Mainz Biomed | Pivotal Trial |